A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Siew-Fei Ngu; Hextan Y S Ngan; Karen K L Chan

doi:10.20517/cdr.2022.12

A patient with relapsed high-grade serous ovarian carcinoma with somatic RAD51C mutations treated with PARPi monotherapy: a case report

Cancer Drug Resist. 2022 Jun 22;5(3):662-666. doi: 10.20517/cdr.2022.12. eCollection 2022.

Authors

Siew-Fei Ngu¹, Hextan Y S Ngan¹, Karen K L Chan¹

Affiliation

¹ Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong, China.

Abstract

We report our experience in the management of a relapsed ovarian cancer patient with somatic RAD51C mutation, treated with olaparib monotherapy. The patient was diagnosed with stage 4 high-grade serous ovarian carcinoma and was treated with neoadjuvant chemotherapy, cytoreductive surgery, and postoperative chemotherapy. After a second cancer recurrence, she underwent FoundationOne CDx testing following disease progression on multiple lines of chemotherapy. Based on the FoundationOne CDx results, olaparib monotherapy was started. After 13 months of therapy, all lesions responded to the treatment, and she achieved complete response as demonstrated by normalization of the levels of CA125 and positron emission tomography-computed tomography (PET-CT). We plan to continue olaparib monotherapy until disease progression.

Keywords: BRCA; Ovarian cancer; PARP inhibitor; RAD51C.

Publication types

Case Reports